| Literature DB >> 33110186 |
Fevzi Altuntas1,2, Naim Ata3, Tugce Nur Yigenoglu4, Semih Bascı4, Mehmet Sinan Dal4, Serdal Korkmaz5, Sinem Namdaroglu6, Abdulkadir Basturk7, Tuba Hacıbekiroglu8, Mehmet Hilmi Dogu9, İlhami Berber10, Kursat Dal11, Mehmet Ali Erkurt10, Burhan Turgut12, Mustafa Mahir Ulgu13, Osman Celik14, Abdullah Akunal13, Suayip Birinci15.
Abstract
In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients.Entities:
Year: 2020 PMID： 33110186 DOI： 10.1038/s41409-020-01084-x
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483